Menard Financial Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.36M Buy
2,798
+813
+41% +$831K 1.83% 12
2026
Q1
$1.83M Buy
+1,985
New +$2.01M 1.28% 20
2025
Q3
Sell
-851
Closed -$663K 92
2025
Q2
$663K Sell
851
-30
-3% -$23.3K 0.39% 50
2025
Q1
$683K Buy
881
+71
+9% +$59.1K 0.45% 47
2024
Q4
$625K Buy
810
+49
+6% +$40.6K 0.38% 58
2024
Q3
$674K Buy
761
+17
+2% +$15.3K 0.44% 53
2024
Q2
$674K Buy
744
+28
+4% +$22.4K 0.48% 47
2024
Q1
$557K Buy
+716
New +$510K 0.47% 52

Other funds holding LLY

Menard Financial Group's LLY Position: Q2 2026 in Review

Menard Financial Group increased its Eli Lilly (LLY) stake by 41% in Q2 2026, buying an estimated $831K and bringing the position to 2,798 shares worth $3.36M. The position accounts for 1.83% of the portfolio, ranked #12.

Menard Financial Group first reported a position in LLY in Q1 2024 and has held it in 8 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Menard Financial Group held 2,798 shares of Eli Lilly worth $3.36M as of Q2 2026.
  • Menard Financial Group bought 813 Eli Lilly shares in Q2 2026, an estimated $831K.
  • Eli Lilly made up 1.83% of Menard Financial Group's portfolio in Q2 2026, its #12 holding.
  • Menard Financial Group first reported a position in Eli Lilly in Q1 2024 and has held it in 8 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Menard Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.